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Abstract
Background: The aim of the present study was to evaluate the recovery potential of the parotid glands after using
either 3D-conformal-radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) by sparing one single
parotid gland.
Methods: Between 06/2002 and 10/2008, 117 patients with head and neck cancer were included in this
prospective, non-randomised clinical study. All patients were treated with curative intent. Salivary gland function
was assessed by measuring stimulated salivary flow at the beginning, during and at the end of radiotherapy as
well as 1, 6, 12, 24, and 36 months after treatment. Measurements were converted to flow rates and normalized
relative to rates before treatment. Mean doses (Dmean) were calculated from dose-volume histograms based on
computed tomographies of the parotid glands.
Results: Patients were grouped according to the Dmean of the spared parotid gland having the lowest radiation
exposure: Group I - Dmean < 26 Gy (n = 36), group II - Dmean 26-40 Gy (n = 45), and group III - Dmean >4 0G y( n=
36). 15/117 (13%) patients received IMRT. By using IMRT as compared to 3D-CRT the Dmean of the spared parotid
gland could be significantly reduced (Dmean IMRT vs. 3D-CRT: 21.7 vs. 34.4 Gy, p < 0.001). The relative salivary flow
rates (RFSR) as a function of the mean parotid dose after 24 and 36 months was in group I 66% and 74%, in group
II 56% and 49%, and in group III 31% and 24%, respectively. Multiple linear regression analyses revealed that the
parotid gland dose and the tumor site were the independent determinants 12 and 36 months after the end of RT.
Patients of group I and II parotid gland function did recover at 12, 24, and 36 months after the end of RT.
Conclusions: If a Dmean < 26 Gy for at least one parotid gland can be achieved then this is sufficient to reach
complete recovery of pre-RT salivary flow rates. The radiation volume which depends on tumor site did
significantly impact on the Dmean of the parotids, and thus on the saliva flow and recovery of parotid gland.
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Background
Sparing salivary glands during radiotherapy (RT) is an
important research field in the treatment of head and
neck tumors because avoiding xerostomia or reduction
of hyposalivation improves oral health and quality of life
of the patients [1-3].
The functional changes of the parotid glands as well as
the impact on oral structures depend on radiation dose
and the irradiated volume [4]. Eisbruch et al.s u g g e s t e d
that xerostomia could be avoided until a dose lower than
26 Gy [5]. Recently, a multicenter randomized study
(PARSPORT trial) investigated the advantage of the paro-
tid sparing of intensity-modulated radiotherapy (IMRT)
technique as compared to conventional 3D-conformal-
radiotherapy-technique (3D-CRT) in terms of clinical
outcome [6]. The authors described that after 12 months,
39% of IMRT patients suffered from dry mouth as
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However, Dmean values < 26 Gy of both parotid glands
cannot be achieved in all patients even by using more
advanced 3D-CRT or IMRT during uni- or bilateral
radiotherapy in the head neck region. In addition, a func-
tional recovery could be expected [7]. Moreover, most
studies focusing on the recovery of the salivary glands
after curative radiotherapy had only a follow-up period of
12 months. Just one single study by Braam et al.e x a m -
ined the quality of life and salivary flow rates after irra-
diation of head and neck cancer over a period of 5 years
[8].
At the University Hospital of Halle, Germany, in the
year 2002 an individualized 3D-CRT technique has been
implemented in clinical practice to spare parotid glands
[9]. Since 2007 the IMRT technique was implemented.
The aim of this investigation was to measure of the whole
salivary flow rate 12, 24 and 36 months after the end of
radiotherapy under the circumstances that the protection
of at least one single parotid is achieved either with 3D-
CRT and IMRT. Depending on the radiation dose to the
salivary glands the time of recovery of the parotid glands
should be examined.
Methods
Patients selection
Between 06/2002 and 10/2008, 117 patients (90 male, 27
female, average age: 57 years) with squamous cell carci-
noma of the head and neck were included in a prospective,
non-randomised clinical study. These patients represent a
cross-section of all patients receiving bilateral irradiation
during tumor treatment of head and neck cancer at Mar-
tin-Luther-University Halle-Wittenberg (MLU-Halle),
Germany. The tumors were classified in accordance with
UICC TNM classification. All described schemes corre-
sponded to the criteria of the official guideline. Patients’
characteristics are described in table 1. The protocol was
accepted by the ethics committee of the Martin-Luther-
University Halle-Wittenberg. Study was supported by the
German Cancer Aid e.V. The data in study Grant No.
106386 were prolonged in follow-up, and added to the
data of the IMRT patients enrolled in study Grant No.
108429.
Treatment planning, definition of target volumes and
radiation dose
All patients received 3D-CRT or IMRT, the treatment of
the bilateral neck was indicated, thus they were irra-
diated generally at primary tumor region and addition-
ally regional lymph nodes.
Patients were immobilized with individual thermoplas-
tic head-neck-shoulder masks. A computed tomography
(CT) scan (General Electric Lightspeed, US) with slice
thickness 5 mm of the head and neck region was per-
formed for 3D-CRT or IMRT treatment planning.
The Helax TMS (Version 6.1) and Oncentra Master-
plan (V1.5/3.0 Nucletron B.V., Veenendaal, NL) was used
as 3D treatment planning system. The 3D-CRT was per-
formed by standardized six to seven portals arrangements
[10]. 6 - 10 MV photons of a linear accelerator were used
(Primus or Oncor, Siemens Medical Solutions, Germany).
IMRT was based on the step-and-shoot approach with
Table 1 Patient and tumor characteristics.
Study population
Patient number 117
Male/female 90/27
Median age in years (range) 57 (27 - 88)
Unilaterale/bilaterale radiotherapy 117
3D-CRT/IMRT 102/15
Tumour sites
Oral cavity/Oropharynx 81
Larynx/Hypopharynx 29
Unknown primary (CUP) 2
Other (Myeloma, Lymphoma, Nasal Cavity, Paranasal Sinus) 5
Staging
UICC-I 7
UICC-II 11
UICC-III 34
UICC-IVA 61
UICC-IVB 2
Myeloma and Lymphoma IA/IIA 2
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nique was similar to the previously described one by
Georg et al. [11]. The treatment planning system used
was Oncentra Masterplan (V1.5/3.0, Nucletron B.V., Vee-
nendaal, NL). The planning strategy was to cover 95% of
the PTVs with 95% of the prescribed dose. The mean
dose of at least one parotid gland was limited to 26 Gy
without compromising the PTV, and the maximum dose
to the spinal cord was 45 Gy, Figure 1.
Two different clinical target volumes (CTVs) were deli-
neated: the CTV 1 harbouring the region of the primary
tumor or postoperative tumor bed, including pathologi-
cally lymph nodes. The low dose volume was named
CTV 2 and included the adjuvant treated regions of the
neck without a histological or clinical proof of pathologi-
cal changed lymph nodes. The primary planning target
volume (PTV 1) was defined as CTV 1 with adequate
safety margin of 5 mm. The secondary PTV (PTV 2)
included PTV 1 and different lymph node chains of the
neck (CTV 2) with a safety margin of 5 - 8 mm. The
safety margin could be reduced close to the organs at
risk. PTV 2 was irradiated five days a week, each fraction
with a single dose of 2 Gy, until a cumulative dose of 50
Gy was reached. Afterwards PTV1 was continued to be
irradiated in the same way until a total dose of 64 - 70
Gy. Dose specifications are related to a reference point in
the target volume as described in ICRU reports 50, 62
and 83.
Determination of the parotid gland doses
The planning target volumes and both parotid glands, the
mandible, and the larynx were outlined on the transversal
slices of the planning CT-scans. The planning goal was -
while maintaining a homogeneous dose distribution in the
target volumes - to minimize mean dose in the contra-lat-
eral parotid gland. No effort was undertaken to spare the
submandibular, the sublingual or minor salivary glands.
The mean dose and the partial volumes receiving speci-
fied doses were determined for each gland from dose-
volume histogram (DVH). Based on an algorithm initially
proposed by Lyman the DVHs, which represent non-uni-
form irradiation of the glands, were transformed to single
Figure 1 Recovery potentials 1, 6, 12, 24, and 36 months after end of radiation therapy (RT). The initial flow-rate was 100%. Saliva
measurement was normalized in relation to pre-treatment results in relative salivary flow rates (RSFR’s in %).
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and contralateral parotid glands were calculated for every
patient in Gy (Dmean). The patients were grouped accord-
ing to the Dmean of the lowest irradiated parotid gland:
Group I - Dmean <2 6G y( n=3 6 ) ,g r o u pI I-D mean 26 -
40 Gy (n = 45), and group III - Dmean > 40 Gy (n = 36).
Determination of the saliva flow rate
All patients underwent saliva collection at different stages:
within one week before radiation treatment, 1, 6, 12, 24,
and at least 36 months after the end of RT. All salivary
samples were collected at least one hour after a meal at a
standardized time of the day (9:00 am to 11:00 pm).
Patients were asked to rinse the mouth and swallow any
residual saliva. Then, the patients were instructed to chew
on a paraffin pellet (Ivoclar Vivadent
®, Liechtenstein) for 5
min. After 5 min samples were collected with the patients
expectorating all saliva into cups. Saliva was drawn up into
one way syringes and salivary flow rates were expressed in
millilitre (ml) per 5 min [13,14]. Saliva measurement was
normalized in relation to pre-treatment results in relative
salivary flow rates (RSFRs). In some cases patients pro-
duced a larger amount of saliva after radiotherapy than in
the beginning. These measurements were regarded as free
of complication and as 100 per cent of post therapeutic
salivary flow rate.
Statistics
The statistical analysis was performed using SPSS 17.0 for
Windows. Direct comparisons (paired t tests) were used
for the evaluation of differences in the lowest Dmean par-
otid dose and RSFRs. Comparison of salivary flow rates
(RSFRs) and Dmean of the lowest parotid gland on
months 12, 24 and 36 was accomplished by one-way
ANOVA followed by post-hoc Bonferroni multiple-com-
parison test. Linear regressions were carried out on the
results, assuming a normal distribution of the parameters
Dmean lowest parotid gland, tumor size, T and N stage and
the correlation coefficients were determined. Level of sig-
nificance was set to 5% (p < 0.05).
Results
Mean parotid gland dose of 3D-CRT and IMRT
15/117 (13%) patients received IMRT. In group I the
number of patients with IMRT was 12/36 (33%), in
group II 3/45 (13%) and in group III 0/36 (0%). By use
of IMRT, the mean dose value of the spared parotid
gland was significantly reduced compared to 3D-CRT
(Table 2).
Relative salivary flow rates
During the whole treatment course time the RSFRs
decreased continuously and followed an exponential curve
till 6 months after irradiation. The decline of RSFRs began
directly after initiation of the radiation treatment. The
reduction was already less pronounced in group I as com-
pared to group II and particularly to group III (Table 3).
Six months after radiotherapy the RFSR as compared to
the initial flow rate was decreased to 50% in group I, 33%
in group II, and 13% in group III. The comparison
between group I and II did not demonstrate significant
differences after 6, 12, 24 and 36 months. However, the
comparison between group I and III did reveal significant
differences at all re-examination time points (p < 0.05).
Recovery of parotid glands
After 12, 24, and 36 months in group I and II a recovery
effect could be measured. After 36 months, patients in
group I had reached again about 74% of the initial value
of saliva flow. The recovery during a follow up period of
24 months or 36 months was significant for group I and
group II, whereas in group III no recovery potentials
were measured neither at 12, 24, or 36 months (Figure 1).
Impact of parotid dose, tumor site, tumor- and lymph
node stage
Analysis of the RSFR as a function of the mean parotid
dose between the different tumor sites (oral cavity, oro-
pharynx, and larynx/hypopharynx), T stage and N stage
was performed. A significantly greater parotid flow ratio
after 36 months after RT in favour of the tumor sites lar-
ynx/hypopharynx (62%) and oropharynx (56%) as com-
pared to oral cavity (31%) was shown (Table 4). Multiple
linear regression analyses revealed that the parotid gland
dose and the tumor site were the independent determi-
nants 12 and 36 months after the end of RT (Table 5).
Discussion
Bilateral irradiation in patients with head and neck can-
cer leads to a dose-dependent change of salivary output
Table 2 Mean parotid gland doses with 3D-CRT and IMRT.
IMRT Patients
n
Mean Dose (Gy) Standard Deviation p
Spared (lowest) parotid
gland
No 102 34.4 13.6 0.001
Spared (lowest) parotid
gland
Yes 15 21.7 6.2
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glands in oral cavity are a part of mucosal target volume.
The submandibular glands just as sublingual glands
reside in the midst of level I. Recently Wang et al.h a v e
shown that with modern IMRT a partial sparing of single
submandibular gland is probably feasible [17]. By conse-
quently performed radiation treatment of carcinomas of
the oral cavity, the oropharynx, and the larynx/hypophar-
ynx, the sparing of submandibular salivary glands can
only be taken into consideration in special cases. Sparing
of parotid glands as well as submandibular glands with
dose reduction of mucous membranes seems to be the
most effective way to prevent hyposalivation after treat-
ment. 3D-CRT as well as IMRT do allow the generation
of high dose gradients around target volumes, and thus
to spare organs at risk inclusive mucous membranes. In
previous investigations we have proven that sparing the
p a r o t i dg l a n da l o n eb yu s i n g3 D - C R Tp r o d u c e sl e s s
hyposalivation than a conventional radiation technique
(2D-RT) [9].
Recent investigations have shown that more and more
patients can take the advantage from more advanced RT
techniques such as IMRT. In a multicenter randomized
study (PARSPORT trial) the advantage of the parotid
sparing by using IMRT technique as compared to con-
ventional 3D-CRT in terms of clinical outcome was
investigated [6]. The authors found that 12 months after
treatment, 39% of IMRT patients suffered from dry
mouth as compared to 74% of conventional RT. We also
have found that by using IMRT, the mean dose value of
the spared parotid gland was significantly reduced as
compared to 3D-CRT. By using IMRT a mean parotid
gland dose < 26 Gy was reached in 12/15 patients (80%),
and a dose range > 26 to 40 Gy in 3/15 patients (20%).
No patient with IMRT has had a mean dose of > 40 Gy
within the spared parotid gland.
Currently, in the literature only limited data is available
providing long-term salivary flow measurements over sev-
eral years. Solely Braam et al. have demon-strated a recov-
ery concerning a time period of 5 years [8]. Most of the
Table 4 Tumor site with mean and standard deviation of
relative salivary flow rate at 1, 6, 12, 24, and 36 months
after radiotherapy
Tumor site Patients
(n)
mean
RSFR
(%)
SD
(%)
Oral cavitiy 1 month after RT 29 34.3 32.42
6 months after
RT
29 32.7 35.63
12 months after
RT
28 35.9 37.54
24 months after
RT
14 43.4 37.84
36 months after
RT
13 31,0 28.20
Oropharynx 1 month after RT 51 30.2 27.67
6 months after
RT
47 27.4 29.87
12 months after
RT
41 34.1 33.56
24 months after
RT
30 51.3 34.75
36 months after
RT
16 55.9 39.70
Hypopharynx/
Larynx
1 month after RT 28 42.7 32.32
6 months after
RT
27 42.6 34.50
12 months after
RT
29 53.1 31.90
24 months after
RT
17 59.6 28.94
36 months after
RT
11 61.6 29.99
Table 3 Mean and standard deviation of relative salivary
flow rate at 1, 6, 12, 24, and 36 months after
radiotherapy
Group Patients
(n)
mean RSFR
(%)
SD
(%)
I Dmean < 26
Gy
1 month after
RT
34 55.6 32.71
6 months after
RT
35 50.2 36.44
12 months after
RT
27 59.7 36.46
24 months after
RT
19 65.8 34.10
36 months after
RT
14 74.3 27.85
II Dmean 26-40
Gy
1 month after
RT
40 30.8 26.97
6 months after
RT
40 33.4 31.03
12 months after
RT
37 46.7 33.05
24 months after
RT
26 56.4 31.16
36 months after
RT
17 48.7 33.19
III Dmean > 40
Gy
1 month after
RT
37 17.6 16.84
6 months after
RT
31 12.8 15.05
12 months after
RT
35 19.2 23.21
24 months after
RT
18 30.6 26.68
36 months after
RT
11 24.2 28.55
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Page 5 of 8other analysis did not cover more than 12 months [18,19].
In the present prospective analysis, we have shown results
for a time period of 36 months recovery of the salivary
glands. We assume that most of the recovery processes
have been completed within this period. To demonstrate
dose-related differences in the recovery potential of the
parotid gland, we have divided our patients into 3 groups.
Our separation with Dmean < 26 Gy, 26 - 40 Gy and > 40
Gy was based on common reports from the literature and
was done by reasons of comparison with previous investi-
gations and particularly to complement our own objective
measurements with the investigations of the quality of life
after salivary gland protection [20,21].
As described in other studies hyposalivation can be
prevented by restricting mean parotid gland doses to 26
- 30 Gy [15,22-24]. In our study, nearly one quarter of
the patients did benefit from sparing the parotid gland
by using 3D-CRT. With IMRT this was possible for 75%
of the patients. Three years after irradiation 76% of the
pre-treatment salivary flow can be preserved in this
group. These results are excellent and highlight the sig-
nificant advantage of IMRT as compared to the conven-
tional 3D-CRT-technique [25,26]. With a mean parotid
gland dose lower than 26 Gy, the recovery of salivary
gland function reaches about 74% of the initial value at
3 years. Otherwise, patients with a mean parotid gland
dose above 40 Gy did not show significant recovery
values.
Our analysis of the flow ratio as a function of the
mean parotid dose between the tumor sites oral cavity
and larynx/hypopharynx did demonstrate a significantly
higher parotid flow ratio in favour of the lower sites in
the neck (larynx/hypopharynx) after radiotherapy. Sig-
nificant differences over a time period of 12 and 36
months after end of RT were observed. The indepen-
dent influence of T and N stage could not be demon-
strated clearly also due to the limited number of
patients 24 and 36 months after end of RT.
Taking into consideration the tumor localization, still
one third of the patients received despite the use of 3D-
CRT more than 40 Gy to the spared parotid gland. These
patients suffered a total damage of salivary gland function
after irradiation. In a further study, we have already shown
that the remaining stimulated saliva in these patients is
not able to maintain oral health due to its pH and its buf-
fer capacity [20]. In fact it promotes dental caries [27].
Considering the low pH of 6.4, remineralisation is not pos-
sible any more, instead dentine and root areas are demi-
neralised. Accordingly, dental prearrangements have to
accommodate these circumstances.
We know of some weaknesses in our analysis. At 3
years after irradiation, of 117 initially included patients
only a limited number of patients have been available
for follow-up measurements, respective 14-17-11
patients in group I, II and III. This number of patients
shows the reality concerning investigations of recovery
effects of the salivary glands over a long time period.
We also know that the method of the whole stimulated
salivary flow rate measure resulting in a higher salivary
flow rate compared to the more detailed examination
techniques of parotid gland alone with Lashley cups. But
the method is robust, easy to use and non-invasive,
simulating a physiological situation and showed the
smallest variability for measuring the salivary flow rate
[13,22,28].
Also, we mention the expected anatomical changes of
the parotid glands during the head and neck irradiation
[29]. This is known from studies in centers with the use
of helical tomotherapy. Due to weight loss and tumor
shrinkage especially in head and neck patients the paro-
tid gland is expected to get higher doses than predicted.
Studies, whether these changes have a significant influ-
ence on the salivary flow rates are not available.
Hence, it has to be accepted that approximately three
quarter of IMRT and only one third of 3D-CRT
patient’s benefit from salivary gland sparing by an
increasing of the salivary flow rates do to 12 and 24
months after radiation. However, the aim of the radia-
tion protocol used in this study was to preserve salivary
flow rate as high as possible. Lack of saliva predisposes
the development of atypical, unusual and rapidly pro-
gressive and aggressive dental decay [4,30,31].
Table 5 Multiple linear regression analyses for relative salivary flow rates (RSFRs) in the observation periods 12, 24
and 36 months
Variables RSFRs (%)
of 12 months
after RT
(R
2 = 0.299)
RSFRs (%)
of 24 months
after RT
(R
2 = 0.199)
RSFRs (%)
of 36 months
after RT
(R
2 = 0.416)
ß (SE) p-value ß (SE) p-value ß (SE) p-value
Dmean lowest parotid gland -1.187 (0.244) 0.0001 -0.736 (0.338) 0.034 -1.160 (0.395) 0.006
Tumor site 8.886 (2.815) 0.002 7.796 (4.178) 0.068 11.310 (4.640) 0.021
T stage -2.429 (3.173) 0.446 -5.880 (4.671) 0.214 -10.047 (5.230) 0.064
N stage -2.870 (2.143) 0.184 -2.499 (3.232) 0.443 0.866 (4.153) 0.836
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IMRT provides remarkable success rates as compared to
conventional 3D-CRT in terms of parotid gland sparing.
The IMRT technique should therefore represent the
standard of care for the treatment of head and neck
tumors. Parotid-gland-sparing up to mean doses of 26
Gy proved to be a reliable method to avoid distinct long
lasting xerostomia.
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